Search details
1.
Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation.
Cancer Immunol Immunother
; 71(4): 865-874, 2022 Apr.
Article
in English
| MEDLINE | ID: mdl-34462870
2.
Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence.
J Cell Physiol
; 235(11): 7900-7910, 2020 11.
Article
in English
| MEDLINE | ID: mdl-31943171
3.
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting.
Int J Cancer
; 146(7): 1917-1929, 2020 04 01.
Article
in English
| MEDLINE | ID: mdl-31330065
4.
Neoadjuvant Endocrine Therapy in Breast Cancer: Current Knowledge and Future Perspectives.
Int J Mol Sci
; 21(10)2020 May 16.
Article
in English
| MEDLINE | ID: mdl-32429381
5.
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience.
J Cell Physiol
; 234(6): 7708-7717, 2019 06.
Article
in English
| MEDLINE | ID: mdl-30536609
6.
Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations.
Br J Cancer
; 120(1): 57-62, 2019 01.
Article
in English
| MEDLINE | ID: mdl-30377342
7.
Long-term performance of risk scores for venous thromboembolism in ambulatory cancer patients.
J Thromb Thrombolysis
; 48(1): 125-133, 2019 Jul.
Article
in English
| MEDLINE | ID: mdl-30919253
8.
Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting.
J Cell Physiol
; 233(3): 2313-2323, 2018 Mar.
Article
in English
| MEDLINE | ID: mdl-28710865
9.
Risk factors for locoregional disease recurrence after breast-conserving therapy in patients with breast cancer treated with neoadjuvant chemotherapy: An international collaboration and individual patient meta-analysis.
Cancer
; 124(14): 2923-2930, 2018 07 15.
Article
in English
| MEDLINE | ID: mdl-29723396
10.
A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer.
J Cell Physiol
; 232(6): 1571-1578, 2017 Jun.
Article
in English
| MEDLINE | ID: mdl-27861874
11.
Comparison between CaGene 5.1 and 6.0 for BRCA1/2 mutation prediction: a retrospective study of 150 BRCA1/2 genetic tests in 517 families with breast/ovarian cancer.
J Hum Genet
; 62(3): 379-387, 2017 Mar.
Article
in English
| MEDLINE | ID: mdl-27928164
12.
Body mass index modifies the relationship between γ-H2AX, a DNA damage biomarker, and pathological complete response in triple-negative breast cancer.
BMC Cancer
; 17(1): 101, 2017 Feb 06.
Article
in English
| MEDLINE | ID: mdl-28166748
13.
Safety and efficacy of abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: an Italian multicenter "real life" study.
BMC Cancer
; 17(1): 753, 2017 Nov 10.
Article
in English
| MEDLINE | ID: mdl-29126389
14.
Body Mass Index and Treatment Outcomes in Metastatic Breast Cancer Patients Treated With Eribulin.
J Cell Physiol
; 231(5): 986-91, 2016 May.
Article
in English
| MEDLINE | ID: mdl-26449308
15.
Neoadjuvant Sequential Docetaxel Followed by High-Dose Epirubicin in Combination With Cyclophosphamide Administered Concurrently With Trastuzumab. The DECT Trial.
J Cell Physiol
; 231(11): 2541-7, 2016 Nov.
Article
in English
| MEDLINE | ID: mdl-27187274
16.
Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study.
Breast Cancer Res Treat
; 147(3): 599-607, 2014 Oct.
Article
in English
| MEDLINE | ID: mdl-25234842
17.
Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer.
Ann Surg Oncol
; 21(5): 1575-82, 2014 May.
Article
in English
| MEDLINE | ID: mdl-24522992
18.
Effectiveness and response predictive factors of erlotinib in a non-small cell lung cancer unselected European population previously treated: a retrospective, observational, multicentric study.
J Oncol Pharm Pract
; 19(3): 246-53, 2013 Sep.
Article
in English
| MEDLINE | ID: mdl-23223401
19.
Prognostic Relevance of Neutrophil to Lymphocyte Ratio (NLR) in Luminal Breast Cancer: A Retrospective Analysis in the Neoadjuvant Setting.
Cells
; 10(7)2021 07 03.
Article
in English
| MEDLINE | ID: mdl-34359855
20.
Tgf-ß1 transcriptionally promotes 90K expression: possible implications for cancer progression.
Cell Death Discov
; 7(1): 86, 2021 Apr 22.
Article
in English
| MEDLINE | ID: mdl-33888686